UK markets close in 3 hours
  • FTSE 100

    7,020.87
    +37.37 (+0.54%)
     
  • FTSE 250

    22,535.12
    +63.08 (+0.28%)
     
  • AIM

    1,251.67
    +3.54 (+0.28%)
     
  • GBP/EUR

    1.1518
    +0.0007 (+0.06%)
     
  • GBP/USD

    1.3803
    +0.0018 (+0.13%)
     
  • BTC-GBP

    44,193.55
    -1,276.93 (-2.81%)
     
  • CMC Crypto 200

    1,357.45
    -23.50 (-1.70%)
     
  • S&P 500

    4,170.42
    +45.76 (+1.11%)
     
  • DOW

    34,035.99
    +305.10 (+0.90%)
     
  • CRUDE OIL

    63.53
    +0.07 (+0.11%)
     
  • GOLD FUTURES

    1,780.90
    +14.10 (+0.80%)
     
  • NIKKEI 225

    29,683.37
    +40.68 (+0.14%)
     
  • HANG SENG

    28,969.71
    +176.57 (+0.61%)
     
  • DAX

    15,421.44
    +166.11 (+1.09%)
     
  • CAC 40

    6,263.89
    +29.75 (+0.48%)
     

Nexstim Plc Publishes 2020 Annual Report

  • Oops!
    Something went wrong.
    Please try again later.
Nexstim Oyj
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

Company announcement, Helsinki, 5 March 2021 at 09.00 am (EET)

Nexstim Plc Publishes 2020 Annual Report

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the publication of its 2020 Annual Report. These documents are available on the "Investor Relations" section of the Company's website at nexstim.com/investors/financial-reports-and-presentations.

The Annual Report includes the Report of the Board of Directors, the Financial Statements and Consolidated Financial Statements and the Auditor's Report. A copy of the Annual Report is attached to this announcement.

NEXSTIM PLC

Mikko Karvinen, CEO

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com


Erik Penser Bank AB (Certified Adviser
)
+46 8 463 83 00
certifiedadviser@penser.se

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com

Attachments